The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections
Abstract
Hepatologists are frequently asked to evaluate human immunodeficiency virus (HIV)-infected patients with abnormal liver enzymes and to assess the causal role of medications, such as antiretroviral drugs. Recently, the use of HIV-1 specific non-nucleoside reverse transcriptase inhibitors (NNRTIs), including nevirapine (NVP) and efavirenz (EFV), has been associated with severe hepatic injury. We prospectively studied the incidence of severe hepatotoxicity (grade 3 or 4 change in alanine or aspartate transaminase levels) among 568 patients receiving NNRTI-containing antiretroviral therapy, including 312 and 256 patients prescribed EFV and NVP, respectively. Hepatitis C virus (HCV) and hepatitis B virus (HBV) were detected in 43% and 7.7% of patients, respectively. Severe hepatotoxicity was observed in 15.6% of patients prescribed NVP and 8.0% of those prescribed EFV, but only 32% of NVP and 50% of EFV-associated episodes were detected during the first 12-weeks of therapy. The risk was significantly greater among persons with chronic viral hepatitis (69% of cases) and those prescribed concurrent protease inhibitors (PIs) (82% of cases). Nonetheless, 84% of patients with chronic HCV or HBV did not experience severe hepatotoxicity. Severe hepatotoxicity occurs throughout the course of NNRTI therapy and is more common among patients prescribed nevirapine, those coinfected with HCV or HBV, and those coadministered protease inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
Medication Use and the Risk of Stevens–Johnson Syndrome or Toxic Epidermal Necrolysis
Roujeau, J.-C., Kelly, J. P., Naldi, L., Rzany, B., Stern, R. S., Anderson, T., Auquier, A., Bastuji-Garin, S., Correia, O., Locati, F., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332404 · Cited by 1,465
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients
Benhamou, Y., Bochet, M., Di Martino, V., Charlotte, F., Azria, F., Coutellier, A., Vidaud, M., Bricaire, F., Opolon, P., Katlama, C., et al. (1999) · Hepatology · doi:10.1002/hep.510300409 · Cited by 1,219
The Natural History of Hepatitis C Virus Infection: Host, Viral, and Environmental Factors
Thomas, D. L., Astemborski, J., Rai, R. M., Anania, F. A., Schaeffer, M., Galai, N., Nolt, K., Nelson, K. E., Strathdee, S. A., Johnson, L., et al. (2000) · JAMA · doi:10.1001/jama.284.4.450 · Cited by 1,073
Self-citationStaszewski, S., Morales-Ramirez, J., Tashima, K. T., Rachlis, A., Skiest, D., Stanford, J., Stryker, R., Johnson, P., Labriola, D. F., Farina, D., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912163412501 · Cited by 993
Sulkowski, M. S. (2000) · JAMA · doi:10.1001/jama.283.1.74 · Cited by 950
Self-citationMarzolini, C., Telenti, A., Decosterd, L. A., Greub, G., Biollaz, J., & Buclin, T. (2001) · AIDS · doi:10.1097/00002030-200101050-00011 · Cited by 840
Montaner, J. S. G., Reiss, P., Cooper, D., Vella, S., Harris, M., Conway, B., Wainberg, M. A., Smith, D., Robinson, P., Hall, D., et al. (1998) · JAMA · doi:10.1001/jama.279.12.930 · Cited by 756
den Brinker, M., Wit, F. W. N. M., Wertheim-van Dillen, P. M. E., Jurriaans, S., Weel, J., van Leeuwen, R., Pakker, N. G., Reiss, P., Danner, S. A., Jan Weverling, G., et al. (2000) · AIDS · doi:10.1097/00002030-200012220-00011 · Cited by 390
Racial Differences in the Use of Drug Therapy for HIV Disease in an Urban Community
Moore, R. D., Stanton, D., Gopalan, R., & Chaisson, R. E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403173301107 · Cited by 356
Self-citationHepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy
Martínez, E., Blanco, J. L., Arnaiz, J. A., Pérez-Cuevas, J. B., Mocroft, A., Cruceta, A., Marcos, M. A., Milinkovic, A., García-Viejo, M. A., Mallolas, J., et al. (2001) · AIDS · doi:10.1097/00002030-200107060-00007 · Cited by 349
Monga, H. K., Rodriguez‐Barradas, M. C., Breaux, K., Khattak, K., Troisi, C. L., Velez, M., & Yoffe, B. (2001) · Clinical Infectious Diseases · doi:10.1086/321819 · Cited by 321
D'Aquila, R. T., Hughes, M. D., Johnson, V. A., Fischl, M. A., Sommadossi, J.-P., Liou, S.-H., Timpone, J., Myers, M., Basgoz, N., Niu, M., et al. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-12-199606150-00001 · Cited by 304
Risk Factors for Severe Hepatic Injury After Introduction of Highly Active Antiretroviral Therapy
Núñez, M., Lana, R., Mendoza, J. L., Martín-Carbonero, L., & Soriano, V. (2001) · Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200108150-00002 · Cited by 251
John, M., Flexman, J., & French, M. A. H. (1998) · AIDS · doi:10.1097/00002030-199817000-00010 · Cited by 251
Sulkowski, M. S., Mast, E. E., Seeff, L. B., & Thomas, D. L. (2000) · Clinical Infectious Diseases · doi:10.1086/313842 · Cited by 251
Self-citationSex Differences in Nevirapine Rash
Bersoff-Matcha, S. J., Miller, W. C., Aberg, J. A., van der Horst, C., Hamrick, H. J., Powderly, W. G., & Mundy, L. M. (2001) · Clinical Infectious Diseases · doi:10.1086/317536 · Cited by 207
Pollard, R. B., Robinson, P., & Dransfield, K. (1998) · Clinical Therapeutics · doi:10.1016/s0149-2918(98)80105-7 · Cited by 206
Nevirapine and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis
Fagot, J.-P., Mockenhaupt, M., Bouwes-Bavinck, J.-N., Naldi, L., Viboud, C., & Roujeau, J.-C. (2001) · AIDS · doi:10.1097/00002030-200109280-00014 · Cited by 200
Hepatotoxicity after introduction of highly active antiretroviral therapy
Rodríguez-Rosado, R., García-Samaniego, J., & Soriano, V (1998) · AIDS · doi:10.1097/00002030-199810000-00025 · Cited by 190
Savès, M., Vandentorren, S., Daucourt, V., Marimoutou, C., Dupon, M., Couzigou, P., Bernard, N., Mercié, P., & Dabis, F. (1999) · AIDS · doi:10.1097/00002030-199912030-00002 · Cited by 150
Inhibition of Human Cytochrome P450 Isoforms by Nonnucleoside Reverse Transcriptase Inhibitors
Moltke, L. L., Greenblatt, D. J., Granda, B. W., Giancarlo, G. M., Duan, S. X., Daily, J. P., Harmatz, J. S., & Shader, R. I. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122009728 · Cited by 127
Nelfinavir, Efavirenz, or Both after the Failure of Nucleoside Treatment of HIV Infection
Albrecht, M., Bosch, R. J., Hammer, S. M., Liou, S.-H., Kessler, H. A., Para, M. F., Eron, J. J., Valdez, H., Dehlinger, M., & Katzenstein, D. A. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108093450602 · Cited by 127
Severe hepatitis in three AIDS patients treated with indinavir
Bräu, N., Leaf, H. L., Wieczorek, R. L., & Margolis, D. M. (1997) · The Lancet · doi:10.1016/s0140-6736(05)62700-6 · Cited by 111
Carr, A. D., Morey, A. L., Mallon, P. W. G., Williams, D., & Thorburn, D. R. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04579-7 · Cited by 83
Veronese, L., Rautaureau, J., Sadler, B. M., Gillotin, C., Petite, J. P., Pillegand, B., Delvaux, M. M., Masliah, C., Fosse‐Edorh, S., Lou, Y., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.4.821-826.2000 · Cited by 75
Johnson, S., & Baraboutis, J. G. (2000) · JAMA · doi:10.1001/jama.284.21.2722 · Cited by 71
Severe Hepatic Failure Related to Nevirapine Treatment
Cattelan, A. M., Erne, E. M., Salatino, A., Trevenzoli, M., Carretta, G., Meneghetti, F., & Cadrobbi, P. (1999) · Clinical Infectious Diseases · doi:10.1086/520242 · Cited by 70
The Emerging Roles of Non-Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Therapy
Moyle, G. J. (2001) · Drugs · doi:10.2165/00003495-200161010-00003 · Cited by 49
Sha, B. E., Proia, L. A., & Kessler, H. A. (2000) · JAMA · doi:10.1001/jama.284.21.2717 · Cited by 44
Lucas, G. M., Chaisson, R. E., & Moore, R. D. (2001) · AIDS · doi:10.1097/00002030-200109070-00011 · Cited by 43
Self-citationHaas, D. W., Fessel, W. J., Delapenha, R., Kessler, H. A., Seekins, D. W., Kaplan, M., Ruíz, N., Ploughman, L., Labriola, D., Manion, D. J., et al. (2001) · The Journal of Infectious Diseases · doi:10.1086/318083 · Cited by 37
Value of Epidemiologic Studies in Determining the True Incidence of Adverse Events
Miwa, L. J. (1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440390131016 · Cited by 35
Rey, D., Schmitt, M., Partisani, M., Hess-Kempf, G., Krantz, V., Mautort, E. D., Bernard-Henry, C., Priester, M., Cheneau, C., & Lang, J.-M. (2001) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200108150-00006 · Cited by 25
The Tolerability of Efavirenz after Nevirapine-Related Adverse Events
Clarke, S., Harrington, P., Barry, M. G., & Mulcahy, F. M. (2000) · Clinical Infectious Diseases · doi:10.1086/314026 · Cited by 22
Cited by
Liver-Related Deaths in Persons Infected With the Human Immunodeficiency Virus: The D:A:D Study
(2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.15.1632 · Cited by 1,113
Andrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
van Leth, F., Phanuphak, P., Ruxrungtham, K., Baraldi, E., Miller, S., Gazzard, B., Cahn, P., Lalloo, U., van der Westhuizen, I., Malan, D., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15997-7 · Cited by 684
Konopnicki, D., Mocroft, A., de Wit, S., Antunes, F., Ledergerber, B., Katlama, C., Zilmer, K., Vella, S., Kirk, O., & Lundgren, J. D. (2005) · AIDS · doi:10.1097/01.aids.0000163936.99401.fe · Cited by 569
Soriano, V., Sulkowski, M., Bergin, C., Hatzakis, A., Cacoub, P., Katlama, C., Cargnel, A., Mauss, S., Dieterich, D., Moreno, S., et al. (2002) · AIDS · doi:10.1097/00002030-200204120-00001 · Cited by 444
Self-citation
Metadata
- Authors
- Sulkowski, M. S., Thomas, D. L., Mehta, S. H., Chaisson, R. E., & Moore, R. D.
- Venue
- Hepatology
- Published
- 2002-01
- Volume
- 35
- Issue
- 1
- Pages
- 182-189
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2034482023
- Cited by
- 523
- References
- 35
- FWCI
- 29.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.